Skip to main content

Table 2 Comparison between genes uncovered in this study and other cancers. Literature analysis of the genes not previously reported as deregulated in CRC, but found deregulated in other cancer types. Different expression data information was listed for each gene: i) from our study performed by PCR array technology in CRC (n = 95) as compared to NT (n = 19); ii) from literature data by focusing on expression analysis obtained in other cancers (RNA or protein level) and iii) from other literature data obtained from genetic association, epigenetic and functional studies in other cancers. Bold lines highlight newly deregulated genes in CRC and not associated to other cancers

From: A transcriptome-based protein network that identifies new therapeutic targets in colorectal cancer

Gene Symbol PCR Array Data (CRC vs. NT) Bibliography Data
Fold-change q-value Pathway Type of Cancer Expression Change (vs. NT) Ref. Other data
CEL 15.08 < 0.001 Chol. Met. Pancreas ↓ (RNA) [25] /
Nasopharynx ↑ (RNA) [24] /
PCSK9 6.28 < 0.001 Chol. Met. Lung ↓ (RNA) [23] PCSK9 deficiency reduces liver metastasis [64].
INSIG1 3.69 < 0.001 Chol. Met. Breast ↑ (protein) [65] /
DHCR7 3.56 < 0.001 Chol. Met. / / / /
CYP39A1 3.35 < 0.001 Chol. Met. Cholangiosarcoma ↓ (protein) [66] /
APOL1 2.97 < 0.001 Chol. Met. / / / /
CYP51A1 2.95 < 0.001 Chol. Met. / / / /
HMGCS1 2.79 < 0.001 Chol. Met. / / / Non-synonymous mutation associated to hepatocellular carcinoma [67].
NSDHL 2.61 < 0.001 Chol. Met. / / / /
CYP2B6 2.61 < 0.05 Drug Met. Breast ↑ (RNA) [68] /
Hepatocellular ↑ (RNA) [69]
DHCR24 2.44 < 0.01 Chol. Met. Adrenals ↓ (RNA) [70] /
Prostate ↑ low risk and ↓ advanced (protein) [71]
FDPS 2.40 < 0.001 Chol. Met. Prostate ↑ (protein, RNA) [72, 73] /
SRD5A1 2.37 < 0.001 Drug Met. Non-small cell lung cancer ↑ (RNA) [74] /
Prostate ↑ (RNA, protein) [75] Associated with biological aggressiveness in prostate cancer [76].
Breast ↑ (RNA) [77] /
IDI1 2.37 < 0.001 Chol. Met. / / / Altered expression in response to paclitaxel treatment in ovarian carcinoma (nude mice xenografts) [78].
EPDR1 2.25 < 0.01 Cancer / / / /
CNBP 2.09 < 0.001 Chol. Met. / / / /
FDFT1 2.01 < 0.01 Chol. Met. Gastric ↑ (RNA, protein) [79] The A allele of rs2645429 (promoter) was significantly associated with prostate cancer risk in a Japanese familial population (~increase promoter activity) [80].
Prostate ↑ (RNA) [80]
TM7SF2 1.96 < 0.001 Chol. Met. Adrenocortical tumors ↓ (RNA) [81] /
Follicular thyroid carcinoma ↑ aggressive vs. non-aggressive (RNA) [82]
RIPK2 1.95 < 0.001 Apoptosis Breast ↑ (RNA) [83] KO of RIPK2 in murine model of bladder Cancer induces large tumors and higher incidence of metastases [84].
Oral squamous cell carcinoma ↓ (protein) [85]
SREBF1 1.93 < 0.001 Chol. Met. Hepatocellular ↑ (RNA, protein) [86] /
SORL1 1.90 < 0.01 Chol. Met. Astrocytoma ↑ (RNA) [87] /
GSR 1.82 < 0.05 Drug Met. / / / /
MVK 1.72 < 0.001 Chol. Met. / / / /
GSTM5 −3.92 < 0.001 Drug Met. Barett’s esophagus ↓ (RNA) [27] Associated to DNA hypermethylation in Barett’s adenocarcinoma [27], in human salivary gland adenoid cystic carcinoma [88], in myelodysplasic syndrome [89], in glioblastoma [26].
Glioblastoma [26]
COLEC12 −3.32 < 0.001 Chol. Met. Anaplastic thyroid carcinoma ↓ (RNA) [90] /
GSTM2 −3.10 < 0.001 Drug Met. Barett’s esophagus ↓ (RNA) [27] Associated to DNA hypermethylation [27, 91].
Oral squamous cell carcinoma [91]
GSTM3 −2.49 < 0.001 Drug Met. Barett’s esophagus ↓ (RNA) [27] Associated to DNA hypermethylation in Barett’s adenocarcinoma [27].
Lung [92]
CD27 −2.30 < 0.001 Apoptosis Bladder ↓ (RNA) [93] /
B Cell Lymphoma ↑ (protein) [94]
CLL ↑ (RNA) [95]
TEK −2.30 < 0.001 Cancer Non-small cell lung cancer ↓ (RNA) [96] /
Angiosarcoma ↑ (RNA) [97]
AML and CML [98]
Thyroid ↑ (RNA, protein) [99]
Breast ↑ (protein) [100]
RHOU −1.78 < 0.001 Wnt Prostate ↓ (RNA) [101] /
WNT2B −2.19 < 0.001 Wnt Pancreas ↑ (protein) [102] /
Stomach ↑ (RNA) [103]
Basal carcinoma (skin) ↑ (RNA) [104]
ITGA4 −2.13 < 0.001 Cancer CLL ↑ (RNA, protein) [105] /
ITGB3 −2.11 < 0.001 Cancer Liver ↓ (RNA, protein) [106] /
Ovary ↑ (RNA, protein) [107]
CD40LG −2.09 < 0.001 Apoptosis Inflammatory breast cancer ↑ (RNA) [108] /
CELA3A −2.04 < 0.001 Chol. Met. Mucinous pancreatic cyst ↑ (protein) vs non mucinous [109] /
PRKAA2 −1.96 < 0.001 Chol. Met. Ovary ↑ (RNA) [110] /
CYP2C19 −1.94 < 0.001 Drug Met. Breast ↓ (protein) [68] /
Liver ↑ (RNA) [111]
CYP11A1 −1.85 < 0.001 Chol. Met. Prostate ↓ (RNA) [112] Associated to DNA hypermethylation in prostate cancer [112].
Endometrium [113]
WNT5B −1.83 < 0.001 Wnt CLL ↑ (RNA) [114, 115] /
Uterine leiomyoma [116]
FRZB −1.73 < 0.01 Wnt Liver ↓ (RNA) [117] Associated to DNA hypermethylation in hepatocellular carcinoma [117], medulloblastoma [118] and bladder cancer [119].
Melanoma [120]
Medulloblastoma [118]
Bladder [119]
Gastric [121]
Breast [122]
WNT9A −1.68 < 0.001 Wnt CLL ↑ (RNA) [114, 115] /
STAB2 −1.68 < 0.001 Chol. Met. Liver ↓ (protein) [123] /
  1. Abbreviations: Chol. Met. Lipoprotein signaling and cholesterol metabolism, Drug Met Drug metabolism, Wnt Wnt signaling, Cancer: Cancer pathway; CLL Chronic lymphocytic leukemia, AML Acute myeloid leukemia, CML Chronic myeloid leukemia